Spruce Biosciences, Inc.
SPRB
$55.11
$2.344.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 697.00K | 1.30M | 2.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 697.00K | 1.30M | 2.91M |
| Cost of Revenue | 10.36M | 13.62M | 36.88M | 38.42M | 46.94M |
| Gross Profit | -10.36M | -13.62M | -36.18M | -37.12M | -44.03M |
| SG&A Expenses | 15.75M | 14.99M | 13.31M | 13.55M | 13.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.11M | 28.61M | 50.18M | 51.97M | 60.92M |
| Operating Income | -26.11M | -28.61M | -49.49M | -50.67M | -58.01M |
| Income Before Tax | -37.19M | -38.97M | -47.88M | -48.34M | -55.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.19 | -38.97 | -47.88 | -48.34 | -55.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.19M | -38.97M | -47.88M | -48.34M | -55.45M |
| EBIT | -26.11M | -28.61M | -49.49M | -50.67M | -58.01M |
| EBITDA | -25.84M | -28.59M | -49.46M | -50.63M | -57.97M |
| EPS Basic | -38.31 | -53.32 | -84.62 | -85.78 | -99.02 |
| Normalized Basic EPS | -20.14 | -29.52 | -52.89 | -53.61 | -61.88 |
| EPS Diluted | -38.31 | -53.32 | -84.62 | -85.78 | -99.02 |
| Normalized Diluted EPS | -20.14 | -29.52 | -52.89 | -53.61 | -61.88 |
| Average Basic Shares Outstanding | 3.82M | 3.04M | 2.29M | 2.28M | 2.24M |
| Average Diluted Shares Outstanding | 3.82M | 3.04M | 2.29M | 2.28M | 2.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |